龍光集團(03380.HK):購回2000萬美元優先票據
格隆匯1月14日丨龍光集團(03380.HK)公佈,有關公司發行並於新加坡證券交易所有限公司上市的於2022年到期的本金總額為3億美元年息7.50%的優先票據("2022年票據")。於2022年1月14日,公司已於公開市場購買本金總額為2000萬美元的2022年票據,佔2022年票據發行本金總額約6.67%。購回票據將根據其條款及契約予以註銷。
公司認為,購回其優先票據將減少公司的未來財務開支及降低其財務資產負債水平,故符合公司及其股東的整體利益。公司將繼續監察市場狀況及其財務結構,並可能於適當時候進一步購回其優先票據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.